Operating Lease, Right-of-Use Asset of Century Therapeutics, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Century Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Century Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $16,566,000, a 43% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Century Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $16,566,000 -$12,262,000 -43% 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $27,737,000 -$833,000 -2.9% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $28,232,000 +$8,918,000 +46% 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $28,706,000 +$8,330,000 +41% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $28,828,000 +$4,277,000 +17% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $28,570,000 +$3,577,000 +14% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $19,314,000 -$8,893,000 -32% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $20,376,000 -$8,569,000 -30% 31 Dec 2023 10-K 19 Mar 2025 2024 FY
Q3 2023 $24,551,000 -$4,937,000 -17% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $24,993,000 +$265,000 +1.1% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $28,207,000 +$16,537,000 +142% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $28,945,000 +$17,091,000 +144% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $29,488,000 +$17,451,000 +145% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $24,728,000 +$12,477,000 +102% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $11,670,000 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $11,854,000 +$2,462,000 +26% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $12,037,000 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $12,251,000 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q4 2020 $9,392,000 31 Dec 2020 10-K 17 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.